Bayer AG NA (BAYN HM) stock market data APIs
€36.355
0.05(0.1%)
as of December 12, 2025
Try our APIs with
free plan!
Bayer AG NA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for BAYN.HM.
Prev. Close
36.355
Open
36.4082
High
36.777
Low
36.1705
52 wk Range
18.605-37.035
Market Cap
45 791 M
EPS
1.22
Dividends (Yield)
0.0497
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bayer AG NA data using free add-ons & libraries
Get Bayer AG NA Fundamental Data
Bayer AG NA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-08-08
- EPS/Forecast: 1.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bayer AG NA News
New
Does Bayer’s 88% 2025 Surge Reflect a Real Turnaround After Restructuring and Litigation Hopes?
Wondering if Bayer at €36.50 is a genuine turnaround value play or a classic value trap? This article will walk you through the numbers without the jargon. After years of lacklustre returns, the sto...
Plant Breeding and CRISPR Plants Market Intelligence 2025-2030 Featuring Strategic Analysis of Advanta Seeds, Bayer, Dow, Eurofins, KWS and More
Company Logo Key opportunities in the market include leveraging CRISPR's precision for improved crop traits, meeting food security demands amid climate change, and sustainable agriculture trends Dub...
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
Late Breaking Abstract titled "TargetingSCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of Aramchol...
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome Milestone payment to Evotec expected upon first dosing of first study participant in early 2026 HAMB...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
